Jun 22, 2020 1:00 PM ET
iCrowd Newswire – Jun 22, 2020
The E. coli testing market is expected to reach US$ 2,527.73 million by 2027 from US$ 1,506.95 million in 2019; it is estimated to grow at a CAGR of 6.8% from 2020 to 2027.
E. coli testing is conducted to determine the biotoxicity in healthcare-related applications such as medical, food, life sciences, and environmental sciences. E. coli are gram negative opportunistic bacteria that can cause food- and water-borne infectious diseases and food poisoning. It is also responsible for water contamination that may lead to chronic gastrointestinal diseases. The bacteria have several molecular advantages, which makes it a model organism of choice in various biotechnological researches. The E. coli testing market growth is attributed to factors such as increasing E. coli testing, growing product innovations, and rising research activities. On the other hand, testing challenges is the major factor limit the market growth.
Request sample PDF copy at: https://www.theinsightpartners.com/sample/TIPRE00007152/
A few of the prominent players operating in the E. coli testing market are Bio-Rad Laboratories, Inc; Pro-Lab Diagnostics, Inc.; Abbott (Alere Inc.); IDEXX Laboratories, Inc.; Meridian Bioscience, Inc.; BD; Thermo Fisher Scientific, Inc.; CPI International; Biomerieux Inc.; and Hologic, Inc. The market players are focused on acquisitions of other industry players to sustain their position in the market. For instance, in March, 2019, Meridian acquired GenePOC’s molecular diagnostics business portfolio, with a main objective to leverage the rapid, high-quality diagnostics testing solutions of GenePOC as well as to guide and support the diagnosis for facilitating targeted therapeutic decisions for infectious diseases.
The E. coli testing market, by technology, is segmented monoclonal antibodies, differential light scattering, molecular diagnostics, immunoassays, chromatography, flow cytometry, gel microdroplets, and diagnostic imaging. The monoclonal antibodies segment held the largest share of the market in 2019. Monoclonal antibodies are widely used to detect the strains of E. coli in water and clinical samples, and they can identify a single epitope within an antigen, which is an advantage over the polyclonal antibodies. Thus, it is expected to retain its dominance during the forecast period. However, the immunoassays segment is estimated to register the highest CAGR in the market during the forecast period.
Similarly, various pharmaceutical and biotechnology companies follow good manufacturing practices (GMP), and current good manufacturing practices (cGMP). Rising incidences of infectious diseases are also leading to the diagnosis of E. coli in the samples collected from the patients. The developing regions, such as the Asia Pacific, the Middle East and Africa, and Latin America, have rising incidences of infectious diseases. Therefore, E. coli testing has increased in the diagnostics laboratories and hospitals across these regions. For instance, according to an article “Characterisation of STEC and other diarrheic E. coli isolated on CHROMagar STEC at a tertiary referral hospital, Cape Town,” published in 2018, Shiga toxin was identified that produces E. coli (STEC) as an emerging zoonotic pathogen. The study was carried in a hospital of Cape Town, South Africa, and it has identified that E. coli can cause acute renal failure in children. Therefore, E. coli testing is widely performed across various sectors, in turn, driving its market growth.
Escherichia coli is a large group of foodborne bacteria, found in food and environment, as well as intestines of animals and humans. Although most types of E coli are harmless and help in keeping the digestive tract healthy, a few strains can cause tract infections, respiratory illness, and pneumonia, among others. The majority of instances of food poisoning and infectious diseases is caused due to E. coli. Therefore, it is essential to detect the concentration E. coli in various products. Apart from industrial sectors such as pharmaceutical, biotechnology, and environmental, the food & beverages sector is at a higher risk of E coli contamination. It is imperative for food & beverage companies to detect and monitor the presence of the bacteria before starting production, during the production process, and in the final products.
End User Insights
Based on end user, the E. coli testing market is segmented into commercial or private labs, physician offices, hospitals, public health labs, and academic research institutes. The public health labs segment held the largest share of the market in 2019. However, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.
Merger and acquisitions are the more commonly adopted strategies by companies in the E. coli testing market, which enables them expand their global footprints, and product and service portfolios. The market players adopt the product launches strategy to enlarge their global customer base, which also permits them to maintain their brand name globally.
Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPRE00007152/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.
Email: [email protected]